NCT04333875View on ClinicalTrials.gov

Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis

CompletedOBSERVATIONAL
Enrollment

71

Participants

Timeline

Start Date

March 20, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Aortic Valve Stenosis
Interventions
DEVICE

TAVR or SAVR

Patients with critical aortic stenosis as defined by an AVA \<0.6 cm2 or a transvalvular mean gradient of \>60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to TAVR or SAVR.

Trial Locations (1)

3010

Department of Cardiology, Bern University Hospital, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT04333875 - Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis | Biotech Hunter | Biotech Hunter